BOSTON (江湖电竞最新版比赛(江湖电竞投注app网站)) — Chelsea Therapeutics ranked as the lead gainer in the drug sector Monday, its shares rallying as the biotech company reported positive clinical data for drug candidate Northera.
The shares rocketed nearly 40% to $6.96 in early trading.
Chelsea CHTP reported favorable Phase III data for Northera, a prospective treatment for a chronic type of low blood pressure.
Also higher, Athersys
Athersys said that a study has shown MultiStem, its stem-cell therapy product, was able to help mitigate brain damage in animals that suffered traumatic brain injury. The study will be published in the October issue of the journal Experimental Neurology.
More broadly, the drug sector’s two main indexes moved marginally higher.
The NYSE Arca Pharmaceutical Index